These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21342029)

  • 1. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
    Addeo R; Caraglia M
    Expert Rev Anticancer Ther; 2011 Feb; 11(2):139-42. PubMed ID: 21342029
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecularly targeted therapy in breast cancer: the new generation.
    Nahleh ZA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):100-4. PubMed ID: 18537752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib in second-line treatment for metastatic breast cancer: rapid clinical benefit and long-term response.
    De Tursi M; Carella C
    Tumori; 2013; 99(6):261e-3e. PubMed ID: 24503799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
    Spraggs CF; Parham LR; Song K; Briley LP; Johnson T; Russo M; Tada H; du Bois A; Xu CF
    Ann Oncol; 2015 Jul; 26(7):1515-7. PubMed ID: 25922065
    [No Abstract]   [Full Text] [Related]  

  • 6. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.
    Melisko ME; Glantz M; Rugo HS
    Nat Clin Pract Oncol; 2009 Jan; 6(1):25-33. PubMed ID: 18936791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.
    Azim HA; Azim HA
    Future Oncol; 2012 Feb; 8(2):135-44. PubMed ID: 22335578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in research on treatment of breast cancer with lapatinib].
    Ma CD; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):321-4. PubMed ID: 18953827
    [No Abstract]   [Full Text] [Related]  

  • 9. Three new drugs available to fight kidney cancer.
    Bankhead C
    J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
    [No Abstract]   [Full Text] [Related]  

  • 10. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are volumetric changes of brain metastases the best evaluation of efficacy?
    Belkacémi Y; Kuten A
    J Clin Oncol; 2008 Nov; 26(31):5137-8; author reply 5138-9. PubMed ID: 18838700
    [No Abstract]   [Full Text] [Related]  

  • 12. Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib.
    Zeng H; Li X; Yao J; Zhu Y; Liu J; Yang Y; Qiang W
    Urol Int; 2009; 83(4):482-5. PubMed ID: 19996660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
    Tomasello G; Bedard PL; de Azambuja E; Lossignol D; Devriendt D; Piccart-Gebhart MJ
    Crit Rev Oncol Hematol; 2010 Aug; 75(2):110-21. PubMed ID: 20004109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiological response of brain metastases to novel tyrosine kinase inhibitor lapatinib.
    Ammannagari N; Ahmed S; Patel A; Bravin EN
    QJM; 2013 Sep; 106(9):869-70. PubMed ID: 23596263
    [No Abstract]   [Full Text] [Related]  

  • 15. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 16. Brain metastasis in renal cell cancer responding to sunitinib.
    Koutras AK; Krikelis D; Alexandrou N; Starakis I; Kalofonos HP
    Anticancer Res; 2007; 27(6C):4255-7. PubMed ID: 18214028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer.
    Duchnowska R; Loibl S; Jassem J
    Cancer Treat Rev; 2018 Jun; 67():71-77. PubMed ID: 29772459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
    Sardesai SD; Storniolo AM
    Womens Health (Lond); 2015 Jun; 11(3):281-94. PubMed ID: 26102468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology Annual Meeting 2013.
    Yaqub F
    Lancet Respir Med; 2013 Jul; 1(5):360-1. PubMed ID: 24429195
    [No Abstract]   [Full Text] [Related]  

  • 20. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.